OncoMatch/Clinical Trials/NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Is NCT06890598 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Olomorasib and Pembrolizumab for carcinoma, non-small-cell lung.
Treatment: Olomorasib · Pembrolizumab · Durvalumab — The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C mutation
Must have disease with evidence of KRAS G12C mutation.
Required: PD-L1 (CD274) expression (known)
Must have known programmed death-ligand 1 (PD-L1) expression
Required: EGFR alteration
Have known changes in the EGFR or ALK genes.
Required: ALK alteration
Have known changes in the EGFR or ALK genes.
Disease stage
Required: Stage II, IIIA, IIIB (N2), III
Part A: Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection. Part B: Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clearview Cancer Institute · Huntsville, Alabama
- Infirmary Cancer Care · Mobile, Alabama
- The University of Arizona Cancer Center - North Campus · Tucson, Arizona
- Highlands Oncology Group · Springdale, Arkansas
- UCLA Hematology/Oncology - Santa Monica · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06890598 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS G12C mutation is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR alteration is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB (N2) or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify